Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer

MT Newswires Live

2025/03/13

Mainz Biomed (MYNZ) said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.

The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.

Under the agreement, Mainz Biomed will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.

The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.

MYNZ shares were 0.8% higher in recent premarket activity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2519183168"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2519183168\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2519183168?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-13 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2519183168","market":"hk","top_or_hot":-1,"title":"Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer","media":"MT Newswires Live","content":"<html><body><p> Mainz Biomed (MYNZ) said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.</p><p>The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.</p><p>Under the agreement, Mainz Biomed will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.</p><p>The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.</p><p>MYNZ shares were 0.8% higher in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMainz Biomed, Liquid Biosciences Partner on Blood-Based Test for Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-13 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Mainz Biomed (MYNZ) said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.</p><p>The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.</p><p>Under the agreement, Mainz Biomed will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.</p><p>The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.</p><p>MYNZ shares were 0.8% higher in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYNZ","symbol_name":"Mainz Biomed NV","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2519183168","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2519183168","pubTimestamp":1741870935,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Mainz Biomed  said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.Under the agreement, Mainz Biomed will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.MYNZ shares were 0.8% higher in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYNZ":"Mainz Biomed NV","BK4139":"生物科技"},"translate_title":"Mainz Biomed与Liquid Biosciences合作开展基于血液的胰腺癌检测","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYNZ":1},"content_text":"Mainz Biomed (MYNZ) said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.Under the agreement, Mainz Biomed will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.MYNZ shares were 0.8% higher in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}